182 related articles for article (PubMed ID: 20142835)
21. Impact of activated invariant natural killer T cells on the expansion of regulatory T cell precursors in murine thymocytes in vitro.
Katsumata H; Ikemiyagi M; Hirai T; Kanzawa T; Ishii R; Miyairi S; Fukuda H; Saiga K; Okumi M; Ishii Y; Yokoo T; Tanabe K
Immunol Lett; 2019 Feb; 206():41-48. PubMed ID: 30503823
[TBL] [Abstract][Full Text] [Related]
22. Miscarriage induced by adoptive transfer of dendritic cells and invariant natural killer T cells into mice.
Negishi Y; Ichikawa T; Takeshita T; Takahashi H
Eur J Immunol; 2018 Jun; 48(6):937-949. PubMed ID: 29520760
[TBL] [Abstract][Full Text] [Related]
23. Dendritic cells combined with tumor cells and α-galactosylceramide induce a potent, therapeutic and NK-cell dependent antitumor immunity in B cell lymphoma.
Escribà-Garcia L; Alvarez-Fernández C; Tellez-Gabriel M; Sierra J; Briones J
J Transl Med; 2017 May; 15(1):115. PubMed ID: 28549432
[TBL] [Abstract][Full Text] [Related]
24. Transient Foxp3(+) regulatory T-cell depletion enhances therapeutic anticancer vaccination targeting the immune-stimulatory properties of NKT cells.
Mattarollo SR; Steegh K; Li M; Duret H; Foong Ngiow S; Smyth MJ
Immunol Cell Biol; 2013 Jan; 91(1):105-14. PubMed ID: 23090488
[TBL] [Abstract][Full Text] [Related]
25. Antigen mRNA-transfected, allogeneic fibroblasts loaded with NKT-cell ligand confer antitumor immunity.
Fujii S; Goto A; Shimizu K
Blood; 2009 Apr; 113(18):4262-72. PubMed ID: 19164596
[TBL] [Abstract][Full Text] [Related]
26. Tumor cells loaded with α-galactosylceramide promote therapeutic NKT-dependent anti-tumor immunity in multiple myeloma.
Hong S; Lee H; Jung K; Lee SM; Lee SJ; Jun HJ; Kim Y; Song H; Bogen B; Choi I
Immunol Lett; 2013; 156(1-2):132-9. PubMed ID: 24148970
[TBL] [Abstract][Full Text] [Related]
27. Vaccination with antigen-transfected, NKT cell ligand-loaded, human cells elicits robust in situ immune responses by dendritic cells.
Shimizu K; Mizuno T; Shinga J; Asakura M; Kakimi K; Ishii Y; Masuda K; Maeda T; Sugahara H; Sato Y; Matsushita H; Nishida K; Hanada K; Dorrie J; Schaft N; Bickham K; Koike H; Ando T; Nagai R; Fujii S
Cancer Res; 2013 Jan; 73(1):62-73. PubMed ID: 23108144
[TBL] [Abstract][Full Text] [Related]
28. Invariant natural killer T cells: innate-like T cells with potent immunomodulatory activities.
Wu L; Gabriel CL; Parekh VV; Van Kaer L
Tissue Antigens; 2009 Jun; 73(6):535-45. PubMed ID: 19392798
[TBL] [Abstract][Full Text] [Related]
29. Dendritic cell function can be modulated through cooperative actions of TLR ligands and invariant NKT cells.
Hermans IF; Silk JD; Gileadi U; Masri SH; Shepherd D; Farrand KJ; Salio M; Cerundolo V
J Immunol; 2007 Mar; 178(5):2721-9. PubMed ID: 17312114
[TBL] [Abstract][Full Text] [Related]
30. Novel thioglycoside analogs of α-galactosylceramide stimulate cytotoxicity and preferential Th1 cytokine production by human invariant natural killer T cells.
Melo AM; Zhang L; Dockry ÉF; Petrasca A; Ghnewa YG; Breen EP; Morrissey ME; O'Reilly C; Bruen R; O'Meara A; Lysaght J; Zhu X; Doherty DG
Glycobiology; 2018 Jul; 28(7):512-521. PubMed ID: 29688330
[TBL] [Abstract][Full Text] [Related]
31. NKT Cell-Driven Enhancement of Antitumor Immunity Induced by Clec9a-Targeted Tailorable Nanoemulsion.
Lam PY; Kobayashi T; Soon M; Zeng B; Dolcetti R; Leggatt G; Thomas R; Mattarollo SR
Cancer Immunol Res; 2019 Jun; 7(6):952-962. PubMed ID: 31053598
[TBL] [Abstract][Full Text] [Related]
32. Attenuation of invariant natural killer T-cell anergy induction through intradermal delivery of alpha-galactosylceramide.
Bontkes HJ; Moreno M; Hangalapura B; Lindenberg JJ; de Groot J; Lougheed S; van der Vliet HJ; van den Eertwegh AJ; de Gruijl TD; von Blomberg BM; Scheper RJ
Clin Immunol; 2010 Sep; 136(3):364-74. PubMed ID: 20570567
[TBL] [Abstract][Full Text] [Related]
33. DC therapy induces long-term NK reactivity to tumors via host DC.
Shimizu K; Fujii S
Eur J Immunol; 2009 Feb; 39(2):457-68. PubMed ID: 19180466
[TBL] [Abstract][Full Text] [Related]
34. Activation of invariant Natural Killer T lymphocytes in response to the α-galactosylceramide analogue KRN7000 encapsulated in PLGA-based nanoparticles and microparticles.
Macho Fernandez E; Chang J; Fontaine J; Bialecki E; Rodriguez F; Werkmeister E; Krieger V; Ehret C; Heurtault B; Fournel S; Frisch B; Betbeder D; Faveeuw C; Trottein F
Int J Pharm; 2012 Feb; 423(1):45-54. PubMed ID: 21575695
[TBL] [Abstract][Full Text] [Related]
35. Depletion of CD4+CD25+ regulatory T cells enhances natural killer T cell-mediated anti-tumour immunity in a murine mammary breast cancer model.
Hong H; Gu Y; Zhang H; Simon AK; Chen X; Wu C; Xu XN; Jiang S
Clin Exp Immunol; 2010 Jan; 159(1):93-9. PubMed ID: 19817769
[TBL] [Abstract][Full Text] [Related]
36. Administration of alpha-galactosylceramide impairs the survival of dendritic cell subpopulations in vivo.
Simkins HM; Hyde E; Farrand KJ; Ong ML; Degli-Esposti MA; Hermans IF; Ronchese F
J Leukoc Biol; 2011 May; 89(5):753-62. PubMed ID: 21297009
[TBL] [Abstract][Full Text] [Related]
37. Therapeutic effect of alpha-galactosylceramide-loaded dendritic cells genetically engineered to express SLC/CCL21 along with tumor antigen against peritoneally disseminated tumor cells.
Matsuyoshi H; Hirata S; Yoshitake Y; Motomura Y; Fukuma D; Kurisaki A; Nakatsura T; Nishimura Y; Senju S
Cancer Sci; 2005 Dec; 96(12):889-96. PubMed ID: 16367909
[TBL] [Abstract][Full Text] [Related]
38. Fully Synthetic Invariant NKT Cell-Dependent Self-Adjuvanting Antitumor Vaccines Eliciting Potent Immune Response in Mice.
Chen PG; Hu HG; Sun ZY; Li QQ; Zhang BD; Wu JJ; Li WH; Zhao YF; Chen YX; Li YM
Mol Pharm; 2020 Feb; 17(2):417-425. PubMed ID: 31841011
[TBL] [Abstract][Full Text] [Related]
39. Costimulatory activation of murine invariant natural killer T cells by toll-like receptor agonists.
Kulkarni RR; Villanueva AI; Elawadli I; Jayanth P; Read LR; Haeryfar SM; Sharif S
Cell Immunol; 2012; 277(1-2):33-43. PubMed ID: 22795895
[TBL] [Abstract][Full Text] [Related]
40. Natural Killer T-Cell Agonist α-Galactosylceramide and PD-1 Blockade Synergize to Reduce Tumor Development in a Preclinical Model of Colon Cancer.
Wang Y; Bhave MS; Yagita H; Cardell SL
Front Immunol; 2020; 11():581301. PubMed ID: 33193386
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
